Kornimate/medical-research-clean huggingface dataset:
risk factors for sub mucosal fibrosis during achalasia cardia: a prospective study

Conditions: Esophagus Disorder

Summary: classification for stasis esophagitis: grade i grade ii grade iii vascular pattern obscured obscured obscured mucosal thickening no yes yes ulceration no yes yes nodularity no no yes

predictors of submucosal fibrosis: various factors were analysed for prediction of smf including age, gender, stasis esophagitis, type of achalasia, duration of disease, lower esophageal sphincter pressure (lesp), height of barium column on barium esophagogram and severity of symptoms (eckardt score). esophageal mucosa was graded for the severity of stasis esophagitis (grade i to grade iii) based on vascular pattern, mucosal thickening, ulceration and nodularity. smf was graded (i minimal, ii moderate, iii severe) according to mucosal lift, difficulty in entry, density of sm fibers, separation of mucosa and muscle.

Eligibility criteria:
inclusion criteria: * patients (between 18 to 75 years of age) who underwent poem for achalasia or other esophageal motility disorders. * had a diagnosis of esophageal achalasia confirmed by high resolution manometry, barium esophagogram. exclusion criteria: * patients who underwent treatment other than achalasia * lost to follow up patients. * incomplete clinical record patients * patients not willing to participate in the study
partner ii trial: placement of aortic transcatheter valves ii - high risk and nested registry 7

Conditions: Symptomatic Severe Aortic Stenosis

Summary: the purpose of this trial is to determine the safety and effectiveness of the edwards sapien 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis, and are in high risk.

this is a prospective, non-randomized, multi-center trial for patients undergoing aortic valve replacement with the edwards sapien 3 thv for severe aortic stenosis. patient cohorts will include those inoperable and those considered as a high surgical risk (sts ≥8%). the study also includes nr7 patients (patients with a 20mm vessel size).

Eligibility criteria:
inclusion criteria: 1. patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient \>40 mmhg or jet velocity greater than 4.0 m/s and an initial aortic valve area (ava) of ≤0.8 cm2 or indexed eoa \< 0.5 cm2/m2. qualifying echo must be within 60 days of the date of the procedure. 2. patient is symptomatic from his/her aortic valve stenosis, as demonstrated by nyha functional class ii or greater. 3. the heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient. 4. the study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the institutional review board (irb) of the respective clinical site. 5. the study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up. 6. sts \> 8 exclusion criteria: 1. pre-existing mechanical or bioprosthetic valve in any position. 2. active bacterial endocarditis within 6 months (180 days) of procedure. 3. echocardiographic evidence of intracardiac mass, thrombus or vegetation. 4. any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure. implantation of a permanent pacemaker or icd is not considered exclusion criteria. 5. aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.

Keywords: sapien 3 transfemoral transapical transaortic tavi aortic stenosis thv aortic valve transcatheter heart valve tavr
the effect of sound-insulated music playing and fıgured mask nebulızer application on the processing anxiety of children

Conditions: Anxiety; Child, Only

Summary: the goal of this is a randomized controlled intervention study. the study was carried out to determine the effect of nebulization treatment applied to 3-6-year-old children with a soundproof, music player and figured mask nebulizer on the child's anxiety during the procedure. the study was completed with 120 children who were admitted to the emergency room and would receive inhalation therapy. there are 3 groups in the study. these were intervention group 1 using sound-insulated music and nebulizer with figured mask, intervention group 2 using silent nebulizer, and control group using nebulizer used in routine.

this is a randomized controlled intervention study. the research was carried out in kütahya health sciences university evliya çelebi training and research hospital paediatrics emergency service between 1st may 2022 and 1st june 2022. the study was completed with 120 children who were admitted to the emergency room and would receive inhalation therapy. there are 3 groups in the study. these were intervention group 1 using sound-insulated music and nebulizer with figured mask, intervention group 2 using silent nebulizer, and control group using nebulizer used in routine. in order to collect data, descriptive information form, state trait anxiety inventory for parents, child fear scale and child emotional indicators scale were used. the data obtained in the study were evaluated with the ibm spss statistics 24 (statistical package for social sciences) package program.

Eligibility criteria:
inclusion criteria: * the child should be between the ages of 3-6, * will receive inhaler treatment, * the mother or father should be with the child during the procedure, * not have used any sedative drugs in the last 8 hours before the application, * written consent has been obtained from the parents after the procedure, * the child is not crying before the start exclusion criteria: * the child is younger than 3 years old, older than 6 years oldu, * the childe has a mental disability, * communication with the parent havinh a problem (they cannot understand and speak turkish, etc.), * the child has pain, * the child is the terminal period, * the parent has a situation that prevents the assessment of the scale (mental disability, etc.)

Keywords: mask child anxiety nebulizer atraumatic care
efficacy of rectal sheath analgesia after midline laparotomy

Conditions: Surgery; Pain Postoperative

Summary: midline laparotomy is commonly used in emergency and elective cancer surgery and patients need effective and safe pain treatment after this type of surgery. nowadays modern anticoagulant therapy may prevent use of central regional blocks in pain management. therefore in the present study the efficacy and safety of rectus sheath analgesia is studied using different administration techniques. the primary aim is the efficacy of the rectus sheath analgesia measured with pain ratings and the amount rescue opioid used. secondary aims were concentrations of local anesthetic, rescue opioid and satisfaction to analgesia method used.


Eligibility criteria:
inclusion criteria: • body mass index over bmi \<35 kg / m2 * not pregnancy/adequate contraception * no contraindications to the local anaesthetic no contraindications to opioid patient controlled analgesia * informed consent obtained exclusion criteria: * • bmi \>35 kg / m2 * pregnant or breast feeding * contraindication to local anaesthetics * contraindication to opioids * not able to use patient controlled analgesia pump * relaparotomy * no informed consent

Keywords: laparotomy pain rectus sheath block
fluoride bioavailability after ingestion of water or foods prepared with fluoridated water

Conditions: Dental Caries; Dental Fluorosis

Summary: the importance of fluoridated water to control caries is well recognized. although the mode of action of fluoridated water is known (related to a slight increase in fluoride concentration in saliva/dental biofilm in individuals living in fluoridated areas), the kinetics of fluoride concentration in saliva after ingestion of food prepared with fluoridated water, either from fluoride remaining in the oral cavity after mastication, or from fluoride returning from salivary secretion is not known in details. therefore, the aim of this study is to assess fluoride bioavailability after ingestion of food prepared with fluoridated water. the study will be in vivo, crossover and double blind, in which 12 adult volunteers will participate. in 4 experimental phases, volunteers will ingest: a. a typical brazilian meal cooked with non-fluoridated water (\<0.1 ppm f); b. a typical brazilian meal cooked with fluoridated water (1 ppm f); c. non fluoridated water (\<0.1 ppm f) and d. fluoridated water (1 ppm f). immediately before and 5, 10, 15, 30, 45, 60, 120, 180 minutes after the ingestion, a blood sample will be collected by digital puncture, and a sample of unstimulated saliva will be collected. fluoride concentration in the samples will be determined by an ion specific electrode adapted for microanalysis. results will be analyzed by anova, with significance limit of 5%.


Eligibility criteria:
inclusion criteria: * good general health * good oral health * normal salivary flow rate exclusion criteria: * gastric disorders * renal disorders * systemic diseases * use of drugs that alter salivary flow rate/renal excretion

Keywords: pharmacokinetics, saliva, plasma, fluoride, dental fluorosis, dental caries
correlation of serum gasdermin-d and nlrp-3 inflammasome levels with gvhd biomarkers and endothelial damage markers in graft-versus-host disease

Conditions: Acute Myeloid Leukemia, Adult; Graft Versus Host Disease; Endothelial Dysfunction

Summary: the investigators aimed to reveal the relationship between serum markers of pyroptosis, gvhd biomarkers and endothelial damage markers in patients who were planned for allogeneic stem cell transplantation for aml and developed gvhd during follow-up. secondary outcomes of the study were to demonstrate the role of pyroptosis in the pathophysiology of gvhd and transplantation-associated endothelial injury using serum plasma samples; the efficacy of gvhd biomarkers used to demonstrate organ-specific involvement; and the efficacy of gvhd biomarkers and endothelial injury markers in predicting the development of gvhd, transplantation-associated endothelial injury and non-relapse mortality.

in the study, in patients who were planned to receive allogeneic stem cell transplantation for aml, pre-transplant period (before and after central catheter insertion) and post-transplant period (+1, +7, +14, +28, +60 and +100 days in the post-transplant period) serum pyroptosis markers (serum gasdermin-d and nlrp-3 inflammasome levels), gvhd biomarkers (reg-3 alpha, st2, elafin, hgf, ilr2-alpha, cxcl 9, cxcl 10, cxcl11, baff, tnf-alpha, i il8, il6 , il18 , i il1-beta , il12 , ifn-gamma) and endothelial damage markers (serums-icam , se-selectin , svcam , ang2 , crp , vwf , factor 8 , ldh , d-dimer , transaminase enzyme levels and before transplantation, the aim of this study was to determine the relationship between basic biomarkers in pyroptosis and biomarkers with high predictive value in gvhd and markers of endothelial damage in patients who develop gvhd during follow-up using nail bed capillaroscopic examination and fibroelastographic evaluation to be performed on the twenty-first and hundredth days after transplantation.the serum samples obtained will be compared with the groups of patients with and without gvhd at the planned 1-year follow-up. patients diagnosed with aml between 15.11.2023 and 15.11.2024 will be included in the study and a total of 2 years of clinical follow-up is planned. in case of loss of participants during follow-up, the study planned to recruit new patients with aml who were scheduled for transplantation between november 15, 2023 and november 15, 2024.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * patients with acute myeloid leukemia undergoing allogeneic bone marrow transplantation * patients followed up by the department of hematology, ankara university faculty of medicine hospitals exclusion criteria: * patients under 18 years of age * patients with non-aml transplant indication * patients not followed up by the department of hematology, ankara university faculty of medicine hospitals

Keywords: acute myeloid leukemia, adult graft versus host disease pyroptotic cell death gasdermin-d nlr family, pyrin domain-containing 3 protein endothelial dysfunction
cystatin-c c-guided vancomycin dosing in critically ill patients: a quality improvement project

Conditions: Methicillin-resistant Staphylococcus Aureus; Sepsis; Critical Illness

Summary: determine if a cystatin c-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.

this is a prospective, quality improvement study that evaluated critically ill patients initiated on intravenous vancomycin. between january 2012 through october 2013, vancomycin was dosed at 15-20mg/kg at an interval guided by creatinine clearance using the cockcroft gault equation (control arm). steady state trough concentrations were assessed prior to the 4th dose of a consistent regimen and compared to the individualized target trough range (10-15mg/l or 15-20mg/l) appropriate for the suspected or documented source of infection. given low overall trough achievement observed with standard care, a quality improvement project was undertaken. after approval by local clinical practice committees with representation from the division of infectious diseases, pharmacy and critical care, a quality improvement project was undertaken to implement a new vancomycin dosing nomogram with dosing intervals based on the chronic kidney disease epidemiology collaborative (ckd-epi) creatinine-cystatin gfr equation, expressed in ml/min. after structured education was provided, the dosing algorithm was rolled out from december 2013 through may 2015 (intervention arm). steady state target vancomycin trough achievement was compared between study arms with and without adjustment for potential confounders.

Eligibility criteria:
inclusion criteria: * hospitalized in one of three intensive care units at mayo clinic in rochester, minnesota * suspected or documented gram-positive infection * prescribed iv vancomycin at a consistent dose and scheduled with 8, 12, or 24 hour vancomycin dosing interval exclusion criteria: * vulnerable population * received greater than 1 dose of vancomycin in the 96 hours before icu admission * baseline glomerular filtration rate (gfr) of less than 20 milliliters/minute * undergoing renal replacement therapy * body mass index \> 40kg/m2 * weight \< 40kg
drug-eluting balloon in bifurcations trial

Conditions: Coronary Artery Disease; Atherosclerosis; Stable Angina; Unstable Angina

Summary: the purpose of the debiut study is to assess procedural, clinical and angiographic outcomes of: 1. provisional t-stenting use for dilation the paclitaxel-eluting pci-balloon (diortm) in comparison to dilation with a standard balloon prior to the implant of the liberty bare metal stent in bifurcation lesions (with side branch involvement). 2. comparison of the results above with the results of using a standard balloon prior to provisional t-stenting with the paclitaxel-eluting stent taxustm libertétm.


Eligibility criteria:
inclusion criteria: * stable angina pectoris (ccs class 1,2,3,4) or unstable angina and documented ischemia or silent ischemia * patients eligible for coronary revascularisation * the target bifurcation lesion has a major native coronary artery (\>2.5mm) with a stenosis \> 50% (on visual assessment) located at a side branch (\>2mm) * patient must be acceptable for cabg * de novo lesion * the main vessel lesion can be covered by one stent (up to 32mm) * only one target lesion can be included in the study: other lesions in different vessels are successfully treated before the treatment of the target lesion (residual stenosis \<30%, stent well deployed, no residual dissection, normal timi flow, no chest pain, ecg unchanged compared to pre-procedural ecg) * signed patients informed consent exclusion criteria: * patient unable to give informed consent * patients with a previous pci in the target vessel * patients with in stent restenosis of target lesion * left ventricular ejection fraction more than 30% * patients with left main disease * severe calcifications with an undilatable lesion during balloon predilatation * history of bleeding diathesis * untreated significant lesion greater than 50% diameter stenosis remaining proximal or distal to the target intervention. * patient has suffered a stroke or tia within the past 3 months * life expectancy \< 1 year * any major surgery planned or required during the next 6 months * acute myocardial infarction * only one target lesion can be included in the study * allergy to contrast and/or required anti-platelet medication * patients unwilling to return for follow-up at 6 months
25-hydroxyvitamin d levels are negatively associated with platelets number in a cohort of overweight and obese subjects

Conditions: Obesity

Summary: this study was aimed to investigate the associations between platelet number and 25(oh)d serum concentration in apparently healthy but overweight/obese subjects.

subjects were enrolled at the first examination whether they were not taking any medication, including oral contraceptives or drugs for osteoporosis, and free of significant medical illnesses, except obesity. exclusion criteria were history of endocrinological diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), chronic inflammatory diseases, stable known hypertension, angina pectoris, stroke, transient ischemic attack, heart infarction, congenital heart disease, malignancies, chronic inflammatory diseases, renal and liver failure, angina pectoris, myocardial infarction, heart failure, congenital heart diseases, minor and major stroke, and inherited thrombocytopenias and other major malignancies. subjects were examined by means of the medical history, hormonal, metabolic and routine hematochemical parameters. we provided for a clinical baseline evaluation that included extemporaneous ambulatory blood pressure (bp) and a physical assessment of body weight, body mass index (bmi) and waist circumference (wc) as anthropometric parameters. to lead the statistical analysis, all sample was clusterized into three different groups according to the diagnostic condition of deficiency (\<10 ng/ml), insufficiency (\<20 ng/ml) and sufficiency (≥20 ng/ml) of vitamin d. we labelled each cluster as group 1, group 2 and group 3.

Eligibility criteria:
inclusion criteria: * overweight or obesity (bmi\> 25 kg/m2) exclusion criteria: * any kind of drug * hypertension * endocrine diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), * chronic inflammatory diseases * renal failure * liver failure * angina pectoris * myocardial infarction and heart failure * genetic heart diseases * thrombocytopenias
cognitive-psychophysiological treatment for tics in young people with tourette's syndrome with or without biofeedback

Conditions: Tourette Syndrome; Tics; Tourette Syndrome in Adolescence

Summary: the goal of this clinical trial is to compare the effectiveness of cops therapy with or without the therapeutic component of biofeedback in treating tics in tourette syndrome with emerging young adults. hypotheses: 1. the cops+biofeedback treatment will improve the severity of tics (ygtss) and the clinical global impression, surpassing the clinical significance threshold of cops treatment alone. 2. we expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics. researchers will compare if the biofeedback treatment will improve the severity of tics. * in the pre-test, participants will undergo two interviews, each lasting 3 hours. these interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. a general assessment of intelligence and executive functions will also be conducted. * they will next attend 10 to 12 therapy sessions, with or without biofeedback. (the biofeedback component is explained in more detail in the ''study design'' section). * the post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. the evaluation will be done using the same battery of tests as during the pre-test interview.

\* the project explanations are in english for everyone's ease of understanding, but our study is conducted in french. \*

Eligibility criteria:
inclusion criteria: * have a diagnosis of ts as the main issue, as reported by the participant; * be aged 14 to 21 years inclusive at the start of therapy. exclusion criteria: * present a sensorimotor impairment; * have a diagnosis of intellectual disability (intelligence quotient below 75); * alcohol or drug abuse; * a neurological issue (e.g., hemifacial spasms, huntington's disease); * change medication one month or less before step 1 and up to step 4 (last measurement time) without informing a member of the research team; * simultaneously receive another intervention for tics (e.g., psychologist, massage therapist) without informing a research team member.

Keywords: cops biofeedback cognitive-psychophysiological therapy tourette young adults tics treatment
sorafenib gastric cancer asian phase i study

Conditions: Gastric Cancer

Summary: this study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with s-1 plus cisplatin in asian patients with unresectable / recurrent gastric cancer.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of the primary unresectable or recurrent gastric cancer (both with and without measurable disease by response evaluation criteria in solid tumors (recist) are allowed). peritoneal dissemination without ascites is allowed. * no prior systemic anticancer therapy including chemotherapy, immunotherapy, targeted agents or experimental therapies for advanced disease * prior adjuvant therapy/neo adjuvant therapy is allowed if recurrence occurred 6 months after completion of these therapies * age \>/= 18 years and \< 75 years exclusion criteria: * known brain metastasis, spinal cord compression or meningeal carcinomatosis. * clinically relevant ascites * concurrent cancer that is distinct in primary site or histology from gastric cancer * any condition that impairs patient's ability to swallow whole pills

Keywords: unresectable / recurrent gastric cancer sorafenib s-1 gastric cisplatin cddp